Customer support

xie@china-sinoway.com
EnglishEnglish
banner
Products
Home

API

DASATINIB 302962-49-8

DASATINIB 302962-49-8

USP26, EP, GMP , DMF
  • Product Details

Product Information


Product name

Dasatinib

Molecular Formula

C22H28CIN7O3S

Molecular Weight

506.02

CAS No.

302962-49-8

Quality Standard

USP26, EP, medical grade

Appearance

White powder


COA of Dasatinib


ITEMS

SPECIFICATION

RESULTS

IDENTIFICATION

POSITIVE REACTION

CONFORMS

Water

≤1.5%

0.9%

LOSS ON DRYING

≤0.1%

0.03%

RESIDUE ON IGNITION

≤0.1%

0.02%

CHROMATOGRAPHIC PURITY

RANITIDINE RELATED COMPOUND B≤0.5%

ANY OTHER IMPURITY≤0.3%

THE SUM OF ALL IMPURITIES≤1.0%

CONFORMS

CONFORMS

CONFORMS

ORGANIC VOLATILE IMPURITIES

AS STIPULATED

CONFORMS

ASSAY

(ON DRY SUBSTANCE)

98.0%~102.0%

99.8%

CONCLUSION

CONFORMS TO in house


Usage


Function of Dasatinib

Dasatinib (DASA tin IB), used for all treatment stages (chronic phase, accelerated phase) Stage, lymphoid cell blast crisis and myeloid blast crisis) adult patients. At the same time, the FDA also approved Dasatinib through normal procedures to treat Philadelphia chromosome-positive acute lymphoblastic leukemia adult patients who are resistant or intolerant to other therapies.

Dasatinib inhibits BCR-ABL kinase and SRC family kinases as well as many other selective oncogenic kinases, including c-KIT, ephrin (EPH) receptor kinase and PDGFβ receptor. Dasatinib is a potent, subnanomolar BCR-ABL kinase inhibitor with a strong activity at a concentration of 0.6 to 0.8 nmol. It can be combined with the inactive and active configurations of the BCR-ABL enzyme.

In vitro studies, dasatinib is active in leukemia cell lines expressing various imatinib-sensitive and drug-resistant diseases. The results of these non-clinical studies indicate that dasatinib can overcome imatinib resistance caused by: BCR-ABL overexpression, BCR-ABL kinase region mutations, kinases including SRC family kinases (LYN, HCK) in Over-expression of other signaling pathways within, as well as multidrug resistance genes. In addition, dasatinib can inhibit SRC family kinases at this nanomolar concentration

In an in vivo experiment conducted using the murine CML model alone, dasatinib prevented the progression of chronic phase CML to the acute phase, while prolonging tumor-bearing mice (derived from patient CML cell lines growing in different locations, including the central Nervous system)


*Products under the patent are only for R&D use

Send A Message

If you are interested in our products and want to know more details,please leave a message here,we will reply you as soon as we can.
Related Products

Spironolactone
Spironolactone 52-01-7
EP8, USP38,99.95% up by HPLC, total impurities < 0.05%
Mupirocin powder
Mupirocin 12650-69-0
99% up by HPLC / GMP
Imatinib mesylate
Imatinib Mesylate 220127-57-1
In-house Standard
Ceftiofur sodium
Ceftiofur sodium 104010-37-9
In-house Specification
Thymopentin
Thymopentin 69558-55-0
99% up Medical Grade
Azilsartan
Azilsartan 147403-03-0
99% up, JP/ GMP / PMDA / DMF
Send A Message
Send A Message
If you are interested in our products and want to know more details,please leave a message here,we will reply you as soon as we can.

Home

Products

about

Contact